Impact of long‐term administration of maralixibat on children with cholestasis secondary to Alagille syndrome

Benjamin L. Shneider, Catherine A. Spino, Binita M. Kamath, John C. Magee, Rosalinda V. Ignacio, Suiyuan Huang, Simon P. Horslen, Jean P. Molleston, Alexander G. Miethke, Rohit Kohli, Daniel H. Leung, M. Kyle Jensen, Kathleen M. Loomes, Saul J. Karpen, Cara Mack, Philip Rosenthal, Robert H. Squires, Alastair Baker, Sanjay Rajwal, Deirdre Kelly, Ronald J. Sokol, Richard J. Thompson, for ChiLDReN and UK IMAGO/IMAGINE Investigators – 6 June 2022 – There is growing interest in, but limited data about, intestinal bile acid transport inhibitors as treatment for cholestatic liver disease.

Subscribe to